OPKO Health Reports Q2 2025 Financial Results and Developments

OPKO Health reported Q2 2025 financial results, with consolidated total revenues of $156.8 million, a decrease from $182.2 million in the same period of 2024. The company experienced an operating loss of $60.0 million, slightly improved from the previous year’s loss of $61.7 million. Despite the challenges, OPKO's Board of Directors authorized an additional $100 million for its stock repurchase program.

OPKO Health, Inc. (NASDAQ: OPK) has released its second-quarter 2025 financial results, showing a decline in revenues and an increase in operating losses compared to the same period last year. The company reported consolidated total revenues of $156.8 million, down from $182.2 million in Q2 2024. The operating loss for the quarter was $60.0 million, slightly improved from the previous year’s loss of $61.7 million. Despite these challenges, OPKO's Board of Directors authorized an additional $100 million for its stock repurchase program [1].

The company's revenue decline was primarily driven by a 21.9% year-over-year decrease in services revenues, which amounted to $101.1 million in Q2 2025. This was partly offset by a 0.6% increase in product revenues to $40.7 million. Revenues from the transfer of intellectual property and other also increased by 21.6% to $14.9 million [1].

OPKO Health's gross profit decreased by 4.4% year-over-year to $49.4 million, but the gross margin expanded to 31.5% from 28.4% in the same period last year. Selling, general, and administrative expenses declined by 13.4% to $59.6 million, while research and development expenses increased by 25.9% to $30.3 million [1].

The company's cash and cash equivalents at the end of Q2 2025 stood at $271.7 million, down from $435.9 million at the end of Q1 2025. Cumulative net cash used in operating activities was $117.9 million, up from $62 million a year ago [1].

OPKO Health has revised its financial outlook for 2025, expecting total revenues between $640 million and $660 million, down from the prior outlook of $675 million and $685 million. The company also lowered its expectations for revenues from product sales, services, and other revenues [1].

The company's stock price has been volatile, losing nearly 3.1% during after-hours trading following the release of its Q2 2025 financial results. OPKO Health currently carries a Zacks Rank #4 (Sell) [1].

References:
[1] https://www.nasdaq.com/articles/opk-stock-slips-following-q2-earnings-miss-gross-margin-expands